Palisade Bio (PALI) Operating Income (2010 - 2026)

Palisade Bio (PALI) has 17 years of Operating Income data on file, last reported at -$10.7 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$10.7 million, down 365.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.5 million (down 96.31% YoY), and the FY2025 annual result was -$18.1 million, down 21.52% from the prior year.
• Operating Income eased to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
• Over five years, Operating Income peaked at -$2.3 million in Q1 2025 and troughed at -$10.7 million in Q1 2026.
• A 5-year average of -$4.3 million and a median of -$3.6 million in 2023 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2026: Operating Income jumped 89.13% in 2022, then slumped 365.28% in 2026.
• A 5-year view of Operating Income shows it stood at -$3.8 million in 2022, then grew by 18.04% to -$3.2 million in 2023, then declined by 7.23% to -$3.4 million in 2024, then sank by 195.12% to -$10.0 million in 2025, then declined by 7.68% to -$10.7 million in 2026.
• Business Quant data shows PALI's Operating Income at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.